Company
TalkMed Group Limited
Runs private medical oncology and palliative care practices in Singapore, delivered mainly through Parkway Cancer Centre, with sub-specialty coverage of breast, head and neck, gastro-intestinal, uro-gynaecological and haematological cancers, plus ancillary health services, medical technology services and some overseas operations. The longevity relevance is indirect and delivery-side rather than mechanistic: it is late-stage disease treatment and supportive care, not an ageing-biology intervention. Inclusion rule is met on both limbs (Singapore-headquartered, and formerly SGX Mainboard listed). It is no longer investable on public markets: the shares were delisted with effect from 15 September 2025 after a scheme-of-arrangement privatisation by TW Troy Limited. The former SGX counter code was 5G3; the ticker field is left null because that security no longer trades. The claim that the acquiring vehicle sits under pan-Asian oncology group Tamarind Health was not confirmed by the sources retrieved here, so it is not asserted.
At a glance
- Listing
- No listing on file
- Category
- Healthtech
- Headquarters
- Singapore (101 Thomson Road, #09-02 United Square, Singapore 307591)
- Market cap
- Not disclosed
Thesis
Why it is in this universe
- Category
- Healthtech
- Market
- Singapore
- Recent inflection
- Privatised by scheme of arrangement: shareholders approved the scheme on 15 July 2025, the Singapore court sanctioned it on 18 August 2025, SGX RegCo granted in-principle delisting approval on 21 August 2025, trading was suspended from 9.00 a.m. on 22 August 2025, and the shares were delisted from the SGX Mainboard with effect from 15 September 2025, with the acquirer named in the company announcement as TW Troy Limited (source: TalkMed SGX announcement dated 21 August 2025; delisting date confirmed by sginvestors.io).
- Services
- None recorded
- People tracked
- None on file
Market data
Listing and scale
| Metric | Detail |
|---|---|
| Exchange | Unlisted |
| Ticker | None |
| Secondary listing | None |
| Market cap | Not disclosed |
| Status | Delisted |
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.
Get in touch
Contact
- Address
- Singapore (101 Thomson Road, #09-02 United Square, Singapore 307591)
- Website
- links.sgx.com
- Phone
- No public number published
- No public address published
Offering
What it sells today
No commercial services are recorded for this company yet.
Recent inflection
What moved lately
Privatised by scheme of arrangement: shareholders approved the scheme on 15 July 2025, the Singapore court sanctioned it on 18 August 2025, SGX RegCo granted in-principle delisting approval on 21 August 2025, trading was suspended from 9.00 a.m. on 22 August 2025, and the shares were delisted from the SGX Mainboard with effect from 15 September 2025, with the acquirer named in the company announcement as TW Troy Limited (source: TalkMed SGX announcement dated 21 August 2025; delisting date confirmed by sginvestors.io).
Keep reading
Related coverage from the newsroom.
Sources
What this profile is built on
- Proposed privatisation of TalkMed Group Limited by way of a scheme of arrangement: receipt of in-principle approval for the delisting · TalkMed Group Limited via SGX
- TalkMed Group Limited (SGX: 5G3) stock information · SGinvestors.io
- TalkMed Group corporate site · TalkMed Group Limited
Every entity profile on variis is sourced. Not investment advice.